1 – 5 of 5
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
(
- Contribution to journal › Letter
-
Mark
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
(
- Contribution to journal › Article
- 2019
-
Mark
Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival
(
- Contribution to journal › Article
- 2015
-
Mark
A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.
(
- Contribution to journal › Article
- 2012
-
Mark
The Importance of Being Grade 3: WHO 1999 Versus WHO 2004 Pathologic Grading.
(
- Contribution to journal › Article